MedPath

VM Oncology LLC

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Phase 1
Recruiting
Conditions
Head and Neck Carcinoma
Adenoid Cystic Carcinoma
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Pancreatic Cancer
Mesothelioma
Thymic Carcinoma
Cervical Cancer
Ovarian Cancer
Interventions
First Posted Date
2018-06-14
Last Posted Date
2025-06-24
Lead Sponsor
VM Oncology, LLC
Target Recruit Count
82
Registration Number
NCT03556228
Locations
🇺🇸

Holy Cross Hospital (site 213), Fort Lauderdale, Florida, United States

🇺🇸

Providence Medical Foundation (site 209), Santa Rosa, California, United States

🇺🇸

Hartford Hospital (site 210), Hartford, Connecticut, United States

and more 12 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.